On Feb. 2, 2021, Oragenics announced that the stabilized pre-fusion spike protein CoV-2 S-2P created by the National Institutes of Health and licensed by the Company demonstrated protective immunity in immunized mice challenged with mouse-adapted SARS-CoV-2 virus.